These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 29614689)

  • 1. A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.
    Silajdžić E; Björkqvist M
    J Huntingtons Dis; 2018; 7(2):109-135. PubMed ID: 29614689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biofluid Biomarkers in Huntington's Disease.
    Rodrigues FB; Byrne LM; Wild EJ
    Methods Mol Biol; 2018; 1780():329-396. PubMed ID: 29856027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
    Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.
    Przybyl L; Wozna-Wysocka M; Kozlowska E; Fiszer A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The updated development of blood-based biomarkers for Huntington's disease.
    Zhang S; Cheng Y; Shang H
    J Neurol; 2023 May; 270(5):2483-2503. PubMed ID: 36692635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.
    Rodrigues FB; Byrne LM; Tortelli R; Johnson EB; Wijeratne PA; Arridge M; De Vita E; Ghazaleh N; Houghton R; Furby H; Alexander DC; Tabrizi SJ; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2020 Dec; 12(574):. PubMed ID: 33328328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid Biomarkers for Huntington's Disease.
    Byrne LM; Wild EJ
    J Huntingtons Dis; 2016; 5(1):1-13. PubMed ID: 27031730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluid and imaging biomarkers for Huntington's disease.
    Zeun P; Scahill RI; Tabrizi SJ; Wild EJ
    Mol Cell Neurosci; 2019 Jun; 97():67-80. PubMed ID: 30807825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.
    Fazio P; Paucar M; Svenningsson P; Varrone A
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):85. PubMed ID: 30291526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visualization of prion-like transfer in Huntington's disease models.
    Jansen AH; Batenburg KL; Pecho-Vrieseling E; Reits EA
    Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):793-800. PubMed ID: 28040507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges of Huntington's disease and quest for therapeutic biomarkers.
    Kotrcova E; Jarkovska K; Valekova I; Zizkova M; Motlik J; Gadher SJ; Kovarova H
    Proteomics Clin Appl; 2015 Feb; 9(1-2):147-58. PubMed ID: 25290828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of biomarkers for Huntington's disease.
    Weir DW; Sturrock A; Leavitt BR
    Lancet Neurol; 2011 Jun; 10(6):573-90. PubMed ID: 21601164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do glial cells play an anti-oxidative role in Huntington's disease?
    Gao Y; Chu SF; Li JP; Zuo W; Wen ZL; He WB; Yan JQ; Chen NH
    Free Radic Res; 2014 Oct; 48(10):1135-44. PubMed ID: 24957138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
    Niemelä V; Landtblom AM; Blennow K; Sundblom J
    PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Approach to Tracking Mutant Huntingtin in Biosamples.
    Trajkovic K; Krainc D
    Trends Mol Med; 2018 Dec; 24(12):978-981. PubMed ID: 30509361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Wright DJ; Renoir T; Gray LJ; Hannan AJ
    Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothalamic-endocrine aspects in Huntington's disease.
    Petersén A; Björkqvist M
    Eur J Neurosci; 2006 Aug; 24(4):961-7. PubMed ID: 16925587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory Strategies for Huntington's Disease Treatment.
    Colpo GD; Rocha NP; Stimming EF; Teixeira AL
    CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma neurofilament heavy chain levels in Huntington's disease.
    Wild EJ; Petzold A; Keir G; Tabrizi SJ
    Neurosci Lett; 2007 May; 417(3):231-3. PubMed ID: 17363167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.